Trials / Unknown
UnknownNCT02156297
Sorafenib to Treat FLT3-ITD AML
Sorafenib to Treat AML Patients With FLT3-ITD Mutation: a Non-interventional Cohort Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
It is a prospective, non-interventional, open-label study, in order to observe the safety and response in FLT3-ITD mutation positive AML patients who receiving sorafenib as induction, consolidation, salvage, maintenance or alleviative treatment. The duration of the study from June 2014 through May 2019, with the recruitment duration from June 2014 to May 2017. The inclusion criteria is: 1. Definitely diagnosed as AML 2. FLT3-ITD mutation has been confirmed 3. Accepting the prescription of sorafenib
Conditions
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2020-05-01
- Completion
- 2022-08-01
- First posted
- 2014-06-05
- Last updated
- 2020-02-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02156297. Inclusion in this directory is not an endorsement.